Research programme: small tryptamine derivatives - Marvel Biosciences
Alternative Names: Non-Hallucinogenic Neuroplasticity Program; small tryptamine derivatives - Marvel BiosciencesLatest Information Update: 01 Dec 2023
At a glance
- Originator Marvel Biosciences
- Class Antidepressants; Tryptamines
- Mechanism of Action Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Depressive disorders
Most Recent Events
- 20 Sep 2023 Interim pharmacodynamics data from a preclinical studies in depressive disorders released by Marvel Biosciences (Marvel Biosciences website, September 2023)
- 13 Sep 2023 Preclinical trials in Depressive disorders in Canada (PO) prior to September 2023 (Marvel Biosciences pipeline, September 2023)